nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—Polymenorrhoea—Octreotide—thymus cancer	0.0826	0.098	CcSEcCtD
Fluoxetine—HTR2A—phrenic nerve—thymus cancer	0.0408	0.259	CbGeAlD
Fluoxetine—Hepatic steatosis—Octreotide—thymus cancer	0.0197	0.0234	CcSEcCtD
Fluoxetine—Breast feeding—Octreotide—thymus cancer	0.017	0.0202	CcSEcCtD
Fluoxetine—Goitre—Octreotide—thymus cancer	0.0166	0.0198	CcSEcCtD
Fluoxetine—Osteonecrosis—Octreotide—thymus cancer	0.016	0.0189	CcSEcCtD
Fluoxetine—Hypochromic anaemia—Octreotide—thymus cancer	0.0153	0.0182	CcSEcCtD
Fluoxetine—HTR2A—pulmonary artery—thymus cancer	0.0148	0.0942	CbGeAlD
Fluoxetine—HTR2A—vein—thymus cancer	0.0135	0.0857	CbGeAlD
Fluoxetine—Creatine phosphokinase increased—Octreotide—thymus cancer	0.0113	0.0134	CcSEcCtD
Fluoxetine—Renal pain—Octreotide—thymus cancer	0.0113	0.0134	CcSEcCtD
Fluoxetine—Pregnancy—Octreotide—thymus cancer	0.0105	0.0124	CcSEcCtD
Fluoxetine—Cholecystitis—Octreotide—thymus cancer	0.0104	0.0123	CcSEcCtD
Fluoxetine—Cholelithiasis—Octreotide—thymus cancer	0.00956	0.0113	CcSEcCtD
Fluoxetine—Haematoma—Octreotide—thymus cancer	0.00946	0.0112	CcSEcCtD
Fluoxetine—Hypothyroidism—Octreotide—thymus cancer	0.00926	0.011	CcSEcCtD
Fluoxetine—Galactorrhoea—Octreotide—thymus cancer	0.00917	0.0109	CcSEcCtD
Fluoxetine—Peptic ulcer—Octreotide—thymus cancer	0.0089	0.0106	CcSEcCtD
Fluoxetine—Seborrhoeic dermatitis—Octreotide—thymus cancer	0.00872	0.0104	CcSEcCtD
Fluoxetine—Menstrual disorder—Octreotide—thymus cancer	0.00872	0.0104	CcSEcCtD
Fluoxetine—Paranoia—Octreotide—thymus cancer	0.00872	0.0104	CcSEcCtD
Fluoxetine—Intestinal obstruction—Octreotide—thymus cancer	0.00872	0.0104	CcSEcCtD
Fluoxetine—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.00864	0.0103	CcSEcCtD
Fluoxetine—Neuralgia—Octreotide—thymus cancer	0.00856	0.0102	CcSEcCtD
Fluoxetine—Metrorrhagia—Octreotide—thymus cancer	0.00832	0.00988	CcSEcCtD
Fluoxetine—Neuritis—Octreotide—thymus cancer	0.00796	0.00945	CcSEcCtD
Fluoxetine—Herpes zoster—Octreotide—thymus cancer	0.0079	0.00937	CcSEcCtD
Fluoxetine—Nephrolithiasis—Octreotide—thymus cancer	0.0074	0.00878	CcSEcCtD
Fluoxetine—Petechiae—Octreotide—thymus cancer	0.00723	0.00858	CcSEcCtD
Fluoxetine—Numbness—Octreotide—thymus cancer	0.00717	0.00851	CcSEcCtD
Fluoxetine—Acne—Octreotide—thymus cancer	0.00707	0.00839	CcSEcCtD
Fluoxetine—Sensory loss—Octreotide—thymus cancer	0.00686	0.00815	CcSEcCtD
Fluoxetine—Breast pain—Octreotide—thymus cancer	0.00682	0.00809	CcSEcCtD
Fluoxetine—Jaundice cholestatic—Octreotide—thymus cancer	0.00677	0.00803	CcSEcCtD
Fluoxetine—Amenorrhoea—Octreotide—thymus cancer	0.00677	0.00803	CcSEcCtD
Fluoxetine—Rectal haemorrhage—Octreotide—thymus cancer	0.00658	0.00781	CcSEcCtD
Fluoxetine—Arthropathy—Octreotide—thymus cancer	0.00654	0.00776	CcSEcCtD
Fluoxetine—Herpes simplex—Octreotide—thymus cancer	0.00645	0.00766	CcSEcCtD
Fluoxetine—Drug interaction—Octreotide—thymus cancer	0.00641	0.00761	CcSEcCtD
Fluoxetine—Muscle twitching—Octreotide—thymus cancer	0.00606	0.00719	CcSEcCtD
Fluoxetine—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00595	0.00706	CcSEcCtD
Fluoxetine—Vaginal inflammation—Octreotide—thymus cancer	0.00595	0.00706	CcSEcCtD
Fluoxetine—Hyperkalaemia—Octreotide—thymus cancer	0.00584	0.00693	CcSEcCtD
Fluoxetine—Eructation—Octreotide—thymus cancer	0.00584	0.00693	CcSEcCtD
Fluoxetine—Cystitis noninfective—Octreotide—thymus cancer	0.00581	0.00689	CcSEcCtD
Fluoxetine—Cystitis—Octreotide—thymus cancer	0.00574	0.00682	CcSEcCtD
Fluoxetine—Candida infection—Octreotide—thymus cancer	0.00568	0.00674	CcSEcCtD
Fluoxetine—Vaginal infection—Octreotide—thymus cancer	0.00561	0.00666	CcSEcCtD
Fluoxetine—Neuropathy—Octreotide—thymus cancer	0.00558	0.00663	CcSEcCtD
Fluoxetine—Cramps of lower extremities—Octreotide—thymus cancer	0.00546	0.00648	CcSEcCtD
Fluoxetine—Mouth ulceration—Octreotide—thymus cancer	0.00538	0.00638	CcSEcCtD
Fluoxetine—Urine output increased—Octreotide—thymus cancer	0.00538	0.00638	CcSEcCtD
Fluoxetine—Bladder pain—Octreotide—thymus cancer	0.00538	0.00638	CcSEcCtD
Fluoxetine—Gynaecomastia—Octreotide—thymus cancer	0.00532	0.00631	CcSEcCtD
Fluoxetine—Hyperkinesia—Octreotide—thymus cancer	0.00519	0.00616	CcSEcCtD
Fluoxetine—ORM1—hematopoietic system—thymus cancer	0.00506	0.0321	CbGeAlD
Fluoxetine—Phlebitis—Octreotide—thymus cancer	0.00501	0.00595	CcSEcCtD
Fluoxetine—Sleep disorder—Octreotide—thymus cancer	0.00499	0.00592	CcSEcCtD
Fluoxetine—Thrombophlebitis—Octreotide—thymus cancer	0.00499	0.00592	CcSEcCtD
Fluoxetine—Diabetes mellitus—Octreotide—thymus cancer	0.00496	0.00589	CcSEcCtD
Fluoxetine—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00496	0.00589	CcSEcCtD
Fluoxetine—Polyuria—Octreotide—thymus cancer	0.00492	0.00583	CcSEcCtD
Fluoxetine—Gastroenteritis—Octreotide—thymus cancer	0.00487	0.00578	CcSEcCtD
Fluoxetine—Deafness—Octreotide—thymus cancer	0.00483	0.00573	CcSEcCtD
Fluoxetine—Cardiac failure congestive—Octreotide—thymus cancer	0.00476	0.00565	CcSEcCtD
Fluoxetine—Injury—Octreotide—thymus cancer	0.0047	0.00557	CcSEcCtD
Fluoxetine—Hot flush—Octreotide—thymus cancer	0.00461	0.00548	CcSEcCtD
Fluoxetine—Amnesia—Octreotide—thymus cancer	0.00459	0.00545	CcSEcCtD
Fluoxetine—Menopausal symptoms—Octreotide—thymus cancer	0.00457	0.00543	CcSEcCtD
Fluoxetine—Anaphylactoid reaction—Octreotide—thymus cancer	0.00446	0.00529	CcSEcCtD
Fluoxetine—Arthritis—Octreotide—thymus cancer	0.00444	0.00527	CcSEcCtD
Fluoxetine—Hypoglycaemia—Octreotide—thymus cancer	0.00442	0.00525	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00432	0.00512	CcSEcCtD
Fluoxetine—Osteoarthritis—Octreotide—thymus cancer	0.00432	0.00512	CcSEcCtD
Fluoxetine—SLC6A4—hematopoietic system—thymus cancer	0.00431	0.0274	CbGeAlD
Fluoxetine—Psychotic disorder—Octreotide—thymus cancer	0.00422	0.005	CcSEcCtD
Fluoxetine—Irritability—Octreotide—thymus cancer	0.00412	0.00489	CcSEcCtD
Fluoxetine—Dehydration—Octreotide—thymus cancer	0.00401	0.00476	CcSEcCtD
Fluoxetine—Dry skin—Octreotide—thymus cancer	0.00396	0.0047	CcSEcCtD
Fluoxetine—Gastritis—Octreotide—thymus cancer	0.00382	0.00453	CcSEcCtD
Fluoxetine—Muscular weakness—Octreotide—thymus cancer	0.00381	0.00452	CcSEcCtD
Fluoxetine—Abdominal distension—Octreotide—thymus cancer	0.00376	0.00446	CcSEcCtD
Fluoxetine—Influenza—Octreotide—thymus cancer	0.00373	0.00443	CcSEcCtD
Fluoxetine—Asthma—Octreotide—thymus cancer	0.00373	0.00443	CcSEcCtD
Fluoxetine—Bronchospasm—Octreotide—thymus cancer	0.00367	0.00436	CcSEcCtD
Fluoxetine—Pancreatitis—Octreotide—thymus cancer	0.00366	0.00434	CcSEcCtD
Fluoxetine—Sweating increased—Octreotide—thymus cancer	0.00363	0.00431	CcSEcCtD
Fluoxetine—Bronchitis—Octreotide—thymus cancer	0.00359	0.00426	CcSEcCtD
Fluoxetine—CYP2C19—hematopoietic system—thymus cancer	0.00357	0.0227	CbGeAlD
Fluoxetine—Dysuria—Octreotide—thymus cancer	0.00349	0.00414	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Octreotide—thymus cancer	0.00347	0.00412	CcSEcCtD
Fluoxetine—Pollakiuria—Octreotide—thymus cancer	0.00345	0.00409	CcSEcCtD
Fluoxetine—Weight increased—Octreotide—thymus cancer	0.0034	0.00403	CcSEcCtD
Fluoxetine—Weight decreased—Octreotide—thymus cancer	0.00338	0.00401	CcSEcCtD
Fluoxetine—Hyperglycaemia—Octreotide—thymus cancer	0.00337	0.00399	CcSEcCtD
Fluoxetine—Pneumonia—Octreotide—thymus cancer	0.00335	0.00397	CcSEcCtD
Fluoxetine—Drowsiness—Octreotide—thymus cancer	0.00333	0.00395	CcSEcCtD
Fluoxetine—Depression—Octreotide—thymus cancer	0.00332	0.00394	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Octreotide—thymus cancer	0.00326	0.00387	CcSEcCtD
Fluoxetine—SIGMAR1—cardiac atrium—thymus cancer	0.00325	0.0206	CbGeAlD
Fluoxetine—Jaundice—Octreotide—thymus cancer	0.00324	0.00385	CcSEcCtD
Fluoxetine—ORM1—bone marrow—thymus cancer	0.00324	0.0206	CbGeAlD
Fluoxetine—Urinary tract infection—Octreotide—thymus cancer	0.00323	0.00384	CcSEcCtD
Fluoxetine—Conjunctivitis—Octreotide—thymus cancer	0.00323	0.00384	CcSEcCtD
Fluoxetine—SIGMAR1—pituitary gland—thymus cancer	0.00317	0.0202	CbGeAlD
Fluoxetine—Haematuria—Octreotide—thymus cancer	0.00317	0.00376	CcSEcCtD
Fluoxetine—Epistaxis—Octreotide—thymus cancer	0.00314	0.00372	CcSEcCtD
Fluoxetine—Sinusitis—Octreotide—thymus cancer	0.00312	0.0037	CcSEcCtD
Fluoxetine—HTR2A—neck—thymus cancer	0.00306	0.0195	CbGeAlD
Fluoxetine—Bradycardia—Octreotide—thymus cancer	0.00304	0.00361	CcSEcCtD
Fluoxetine—Rhinitis—Octreotide—thymus cancer	0.00299	0.00355	CcSEcCtD
Fluoxetine—Hepatitis—Octreotide—thymus cancer	0.00299	0.00354	CcSEcCtD
Fluoxetine—Hypoaesthesia—Octreotide—thymus cancer	0.00297	0.00353	CcSEcCtD
Fluoxetine—Pharyngitis—Octreotide—thymus cancer	0.00296	0.00352	CcSEcCtD
Fluoxetine—Oedema peripheral—Octreotide—thymus cancer	0.00294	0.00349	CcSEcCtD
Fluoxetine—ORM1—lung—thymus cancer	0.00294	0.0187	CbGeAlD
Fluoxetine—CYP1A2—hematopoietic system—thymus cancer	0.00292	0.0185	CbGeAlD
Fluoxetine—Visual impairment—Octreotide—thymus cancer	0.00288	0.00342	CcSEcCtD
Fluoxetine—CYP3A5—hematopoietic system—thymus cancer	0.00281	0.0179	CbGeAlD
Fluoxetine—CYP2B6—hematopoietic system—thymus cancer	0.0028	0.0178	CbGeAlD
Fluoxetine—Tinnitus—Octreotide—thymus cancer	0.00278	0.0033	CcSEcCtD
Fluoxetine—CYP2C9—hematopoietic system—thymus cancer	0.00277	0.0176	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—thymus cancer	0.00274	0.0174	CbGeAlD
Fluoxetine—SIGMAR1—thyroid gland—thymus cancer	0.00274	0.0174	CbGeAlD
Fluoxetine—Arrhythmia—Octreotide—thymus cancer	0.00267	0.00317	CcSEcCtD
Fluoxetine—Alopecia—Octreotide—thymus cancer	0.00264	0.00313	CcSEcCtD
Fluoxetine—Mental disorder—Octreotide—thymus cancer	0.00262	0.00311	CcSEcCtD
Fluoxetine—Malnutrition—Octreotide—thymus cancer	0.0026	0.00309	CcSEcCtD
Fluoxetine—Flatulence—Octreotide—thymus cancer	0.00256	0.00304	CcSEcCtD
Fluoxetine—Tension—Octreotide—thymus cancer	0.00255	0.00303	CcSEcCtD
Fluoxetine—Nervousness—Octreotide—thymus cancer	0.00252	0.003	CcSEcCtD
Fluoxetine—Back pain—Octreotide—thymus cancer	0.00251	0.00298	CcSEcCtD
Fluoxetine—SLC6A4—lung—thymus cancer	0.0025	0.0159	CbGeAlD
Fluoxetine—Muscle spasms—Octreotide—thymus cancer	0.0025	0.00297	CcSEcCtD
Fluoxetine—SIGMAR1—lung—thymus cancer	0.00249	0.0158	CbGeAlD
Fluoxetine—Tremor—Octreotide—thymus cancer	0.00244	0.00289	CcSEcCtD
Fluoxetine—Ill-defined disorder—Octreotide—thymus cancer	0.00241	0.00286	CcSEcCtD
Fluoxetine—Anaemia—Octreotide—thymus cancer	0.0024	0.00285	CcSEcCtD
Fluoxetine—Agitation—Octreotide—thymus cancer	0.00239	0.00284	CcSEcCtD
Fluoxetine—Malaise—Octreotide—thymus cancer	0.00234	0.00278	CcSEcCtD
Fluoxetine—Vertigo—Octreotide—thymus cancer	0.00234	0.00277	CcSEcCtD
Fluoxetine—Syncope—Octreotide—thymus cancer	0.00233	0.00277	CcSEcCtD
Fluoxetine—Palpitations—Octreotide—thymus cancer	0.0023	0.00273	CcSEcCtD
Fluoxetine—Loss of consciousness—Octreotide—thymus cancer	0.00228	0.00271	CcSEcCtD
Fluoxetine—HTR2A—hematopoietic system—thymus cancer	0.00228	0.0145	CbGeAlD
Fluoxetine—Cough—Octreotide—thymus cancer	0.00227	0.00269	CcSEcCtD
Fluoxetine—Convulsion—Octreotide—thymus cancer	0.00225	0.00267	CcSEcCtD
Fluoxetine—Hypertension—Octreotide—thymus cancer	0.00224	0.00266	CcSEcCtD
Fluoxetine—Myalgia—Octreotide—thymus cancer	0.00221	0.00263	CcSEcCtD
Fluoxetine—Chest pain—Octreotide—thymus cancer	0.00221	0.00263	CcSEcCtD
Fluoxetine—Arthralgia—Octreotide—thymus cancer	0.00221	0.00263	CcSEcCtD
Fluoxetine—Anxiety—Octreotide—thymus cancer	0.00221	0.00262	CcSEcCtD
Fluoxetine—SLC6A2—lung—thymus cancer	0.0022	0.014	CbGeAlD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.0022	0.00261	CcSEcCtD
Fluoxetine—Discomfort—Octreotide—thymus cancer	0.00219	0.0026	CcSEcCtD
Fluoxetine—Dry mouth—Octreotide—thymus cancer	0.00216	0.00257	CcSEcCtD
Fluoxetine—Anaphylactic shock—Octreotide—thymus cancer	0.00212	0.00252	CcSEcCtD
Fluoxetine—CYP3A4—hematopoietic system—thymus cancer	0.00211	0.0134	CbGeAlD
Fluoxetine—Infection—Octreotide—thymus cancer	0.00211	0.0025	CcSEcCtD
Fluoxetine—Shock—Octreotide—thymus cancer	0.00209	0.00248	CcSEcCtD
Fluoxetine—HTR2A—epithelium—thymus cancer	0.00208	0.0132	CbGeAlD
Fluoxetine—CYP2D6—hematopoietic system—thymus cancer	0.00208	0.0132	CbGeAlD
Fluoxetine—Thrombocytopenia—Octreotide—thymus cancer	0.00208	0.00247	CcSEcCtD
Fluoxetine—Tachycardia—Octreotide—thymus cancer	0.00207	0.00246	CcSEcCtD
Fluoxetine—Skin disorder—Octreotide—thymus cancer	0.00206	0.00245	CcSEcCtD
Fluoxetine—Hyperhidrosis—Octreotide—thymus cancer	0.00205	0.00243	CcSEcCtD
Fluoxetine—Anorexia—Octreotide—thymus cancer	0.00202	0.0024	CcSEcCtD
Fluoxetine—ORM1—lymph node—thymus cancer	0.00201	0.0128	CbGeAlD
Fluoxetine—CYP2B6—lymphoid tissue—thymus cancer	0.00197	0.0125	CbGeAlD
Fluoxetine—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00193	0.00229	CcSEcCtD
Fluoxetine—Insomnia—Octreotide—thymus cancer	0.00192	0.00228	CcSEcCtD
Fluoxetine—Paraesthesia—Octreotide—thymus cancer	0.00191	0.00226	CcSEcCtD
Fluoxetine—Dyspnoea—Octreotide—thymus cancer	0.00189	0.00224	CcSEcCtD
Fluoxetine—Somnolence—Octreotide—thymus cancer	0.00189	0.00224	CcSEcCtD
Fluoxetine—Dyspepsia—Octreotide—thymus cancer	0.00187	0.00222	CcSEcCtD
Fluoxetine—CYP1A2—thyroid gland—thymus cancer	0.00187	0.0118	CbGeAlD
Fluoxetine—Decreased appetite—Octreotide—thymus cancer	0.00184	0.00219	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Octreotide—thymus cancer	0.00183	0.00217	CcSEcCtD
Fluoxetine—Fatigue—Octreotide—thymus cancer	0.00183	0.00217	CcSEcCtD
Fluoxetine—Pain—Octreotide—thymus cancer	0.00181	0.00215	CcSEcCtD
Fluoxetine—Constipation—Octreotide—thymus cancer	0.00181	0.00215	CcSEcCtD
Fluoxetine—ALB—lymph node—thymus cancer	0.00176	0.0112	CbGeAlD
Fluoxetine—Feeling abnormal—Octreotide—thymus cancer	0.00175	0.00208	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Octreotide—thymus cancer	0.00173	0.00206	CcSEcCtD
Fluoxetine—SIGMAR1—lymph node—thymus cancer	0.0017	0.0108	CbGeAlD
Fluoxetine—CYP1A2—lung—thymus cancer	0.00169	0.0108	CbGeAlD
Fluoxetine—HTR2A—pituitary gland—thymus cancer	0.00169	0.0107	CbGeAlD
Fluoxetine—Urticaria—Octreotide—thymus cancer	0.00169	0.002	CcSEcCtD
Fluoxetine—Body temperature increased—Octreotide—thymus cancer	0.00168	0.00199	CcSEcCtD
Fluoxetine—Abdominal pain—Octreotide—thymus cancer	0.00168	0.00199	CcSEcCtD
Fluoxetine—CYP3A5—lung—thymus cancer	0.00163	0.0104	CbGeAlD
Fluoxetine—CYP2B6—lung—thymus cancer	0.00162	0.0103	CbGeAlD
Fluoxetine—Hypersensitivity—Octreotide—thymus cancer	0.00156	0.00186	CcSEcCtD
Fluoxetine—Asthenia—Octreotide—thymus cancer	0.00152	0.00181	CcSEcCtD
Fluoxetine—SLC6A2—lymph node—thymus cancer	0.00151	0.00957	CbGeAlD
Fluoxetine—Pruritus—Octreotide—thymus cancer	0.0015	0.00178	CcSEcCtD
Fluoxetine—ABCB1—hematopoietic system—thymus cancer	0.00149	0.00949	CbGeAlD
Fluoxetine—Diarrhoea—Octreotide—thymus cancer	0.00145	0.00172	CcSEcCtD
Fluoxetine—Dizziness—Octreotide—thymus cancer	0.0014	0.00167	CcSEcCtD
Fluoxetine—ABCB1—epithelium—thymus cancer	0.00137	0.00868	CbGeAlD
Fluoxetine—Vomiting—Octreotide—thymus cancer	0.00135	0.0016	CcSEcCtD
Fluoxetine—Rash—Octreotide—thymus cancer	0.00134	0.00159	CcSEcCtD
Fluoxetine—Dermatitis—Octreotide—thymus cancer	0.00134	0.00159	CcSEcCtD
Fluoxetine—Headache—Octreotide—thymus cancer	0.00133	0.00158	CcSEcCtD
Fluoxetine—HTR2A—lung—thymus cancer	0.00132	0.00841	CbGeAlD
Fluoxetine—Nausea—Octreotide—thymus cancer	0.00126	0.0015	CcSEcCtD
Fluoxetine—ABCB1—pituitary gland—thymus cancer	0.00111	0.00704	CbGeAlD
Fluoxetine—ABCB1—lymphoid tissue—thymus cancer	0.00105	0.00668	CbGeAlD
Fluoxetine—ABCB1—bone marrow—thymus cancer	0.000958	0.00608	CbGeAlD
Fluoxetine—ABCB1—thyroid gland—thymus cancer	0.000956	0.00607	CbGeAlD
Fluoxetine—ABCB1—lung—thymus cancer	0.000868	0.00551	CbGeAlD
Fluoxetine—ABCB1—lymph node—thymus cancer	0.000594	0.00377	CbGeAlD
